Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
2.33 USD +7.37% Intraday chart for Lyell Immunopharma, Inc. -4.51% +20.10%
03-04 North American Morning Briefing : Stock Futures -2- DJ
02-28 Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Lyell Immunopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b540b92177d1236be104c4ddcec0.m5-y08Oi72SUkxOsaVBbfOe6M6PGoVBBIpHLMe5dHNI.y9j0v_XTqQ7wpVfWDj4JOtHdf-SA5AoDG9qaaZRqU5jc7f--hPadIs3wSg~2d1beaf21b8e72bdb6f608c6d3d572d0

Analyst Recommendations on Lyell Immunopharma, Inc.

HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating MT
JPMorgan Downgrades Lyell Immunopharma to Neutral From Overweight, Adjusts Price Target to $5 From $15 MT
HC Wainwright Adjusts Price Target on Lyell Immunopharma to $9 From $11, Maintains Buy Rating MT
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $4 From $7, Maintains Equal Weight Rating MT
Morgan Stanley Downgrades Lyell Immunopharma to Equalweight From Overweight, Adjusts Price Target to $7 From $15 MT
HC Wainwright Starts Lyell Immunopharma at Buy With $12 Price Target MT
Goldman Sachs Adjusts Price Target for Lyell Immunopharma to $12 From $21, Keeps Buy Rating MT
JPMorgan Lowers Price Target for Lyell Immunopharma to $15 From $22, Maintains Overweight Rating MT
Goldman Sachs Adjusts Lyell Immunopharma Price Target to $21 From $31, Maintains Buy Rating MT
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $20 from $25, Keeps Overweight Rating MT
LYELL IMMUNOPHARMA : JPMorgan Starts Lyell Immunopharma at Overweight With $22 Price Target MT
LYELL IMMUNOPHARMA : Morgan Stanley Starts Lyell Immunopharma at Overweight With $25 Price Target MT
LYELL IMMUNOPHARMA : BofA Securities Starts Lyell Immunopharma at Buy With $25 Price Target MT
LYELL IMMUNOPHARMA : Goldman Sachs Starts Lyell Immunopharma at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.33 USD
Average target price
6.333 USD
Spread / Average Target
+171.82%
High Price Target
9 USD
Spread / Highest target
+286.27%
Low Price Target
4 USD
Spread / Lowest Target
+71.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lyell Immunopharma, Inc.

HC Wainwright
JPMorgan Chase
Morgan Stanley
Goldman Sachs
BofA Securities

Ratings for Lyell Immunopharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. Consensus Lyell Immunopharma, Inc.